Abstract 2170
Background
Little is known about the associations between treatment outcome for immune checkpoint inhibitors and metastatic sites in patients with advanced non-small cell lung cancer (NSCLC). Furthermore, these previous studies included patients irrespective of their PD-L1 status and treatment lines. Therefore, we conducted a multicentered retrospective study to investigate the predictive factors of metastatic sites as first-line pembrolizumab efficacy in patients with PD-L1 tumor proportion score (TPS) ≥50% advanced NSCLC.
Methods
We retrospectively analyzed patients with advanced NSCLC and PD-L1 TPS ≥ 50% who received pembrolizumab as the first-line therapy at 11 institutions between February 2017 and April 2018. Clinical data including metastatic sites at the time of administering pembrolizumab treatment were collected. Treatment outcome of pembrolizumab was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Results
In total, 213 patients were included in the study. The median age was 71 years (range 39-91). Of the 213 patients, 176 (83%) were men, 172 (81%) had Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1. The major metastatic sites were thoracic lymph nodes metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). In multivariate analysis, poor PS (hazard ratio: 1.82, 95.0% confidence interval: 1.15–2.30; P = 0.046) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01–2.30; P = 0.046) was identified as an independent predictor of shorter progression free survival in patients treated with pembrolizumab.
Conclusions
In patients with advanced NSCLC and PD-L1 TPS ≥50% who received first-line pembrolizumab, poor PS and malignant pleural effusion are independent predictors of pembrolizumab efficacy.
Clinical trial identification
UMIN000032470.
Editorial acknowledgement
Legal entity responsible for the study
Hanshin Oncology clinical Problem Evaluation group (HOPE).
Funding
Has not received any funding.
Disclosure
H. Kawachi: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. M. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. A. Tamiya: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. K. Hirano: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Yokoyama: Honoraria (self): Taiho Pharmaceutical Co., Ltd. T. Ishida: Honoraria (self): Merck Sharp & Dohme, Corp. D. Fujimoto: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. T. Hirashima: Honoraria (self): Taiho Pharmaceutical Co., Ltd. M. Kanazu: Honoraria (self): Merck Sharp & Dohme, Corp. T. Kumagai: Honoraria (self): Taiho Pharmaceutical Co., Ltd.; Honoraria (self): Merck Sharp & Dohme, Corp. All other authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract